CINCINNATI and BRIDGEWATER, N.J., April 24 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel(R) (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.
The FDA approval of the once-a-month dose is based on a study comparing Actonel 150 mg once monthly to Actonel 5 mg daily. Similar increases in bone mineral density (BMD) were seen among patients taking either once-a-month or daily dosing regimens.
Over fifty-five million prescriptions of Actonel have been filled in the U.S. alone since its approval for osteoporosis in 2000. Those who want to learn more about postmenopausal osteoporosis and treatment with Actonel should visit: http://www.Actonel.com.
Postmenopausal osteoporosis is a silent disease that affects millions of women, making their bones weak and more likely to fracture over time. In fact, in the U.S. today, 8 million women are estimated to already have osteoporosis, and almost 27 million more are estimated to have low bone mass, placing them at increased risk for fracture. Each year the incidence of osteoporosis-related fractures is greater than the incidence of heart attacks, strokes, and breast cancer combined. The good news is that there are prescription medications available that effectively reduce fractures.
Actonel is contraindicated in patients with hypocalcemia, known
hypersensitivity to any component of this product, or inability to stand or
sit upright for at least 30 minutes. Hypocalcemia and other disturbances of
bone and mineral metabolism should be effectively treated before starting
Actonel therapy. Actonel is not recommended for use in patients with severe
renal impairment (creatinine clearance < 30 mL/min).
|SOURCE The Alliance for Better Bone Health|
Copyright©2008 PR Newswire.
All rights reserved